FOXO4-DRI
OtherAlso known as FOXO4 D-Retro-Inverso, Proxofim
Evidence tier
Limited published literature
22 publications over 9 years · trials not yet curated
- Researched since
- 2017
- Publications
- 22
- Mean purity
- 99.1%
- Vendors listing
- 3
PeptidePlugs shows the highest mean assayed purity for FOXO4-DRI at 99.1% across 1 lot record. Purity figures below come from the certificates named in each row.
Score breakdown
The score has two halves: the research base — how long the compound has been studied and how much has been published — and the quality of the evidence the market produces for it, aggregated across every vendor that carries it: assayed purity, lot-to-lot consistency, readable third-party certificates and those vendors’ review record. It measures the evidence base, not the merits or safety of the substance.
Studied since 2017 — 9 years of published research
How long the compound has been studied. Fifteen years or more of published literature earns full marks; a newer compound earns less.
22 publications indexed in PubMed
The volume of published literature located. Full marks at fifty or more publications.
Mean assayed purity 99.1% across 1 certificate
Average assayed purity on the certificates published by vendors that carry this compound. Full marks at 99.5%+, nothing at 95% or below.
single lot on record, mean label deviation 13.3%
How tightly assayed purity and labeled-versus-actual mass hold across different lots. Rewards reproducible manufacturing.
3 of 3 listing vendors publish an accessible certificate policy
Whether the vendors carrying this compound publish per-lot certificates anyone can read without an account.
1 of 1 certificate from a recognised independent lab
Share of certificates issued by a recognised third-party testing lab rather than an unnamed or self-named one.
What is FOXO4-DRI?
A synthetic peptide studied as a senolytic — a compound aimed at clearing senescent cells — in preclinical ageing models.
Studied in published research for clearance of senescent cells (senolytic research).
Regulatory status
Labeled by vendors for laboratory research use only. Not approved as a medicine in the United States, United Kingdom, or European Union.
What the research examines
The areas of published research this compound appears in. These describe what the literature has studied — never a claim of benefit, effect or suitability for any use.
Published research
Published work is preclinical, in cell and animal models of ageing. PepIndex does not evaluate clinical significance and does not describe administration.
- Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression — Circulation (2023)
Peer-reviewed article indexed in PubMed, published in Circulation (2023).
- Senolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes — Frontiers in bioengineering and biotechnology (2021)
Peer-reviewed article indexed in PubMed, published in Frontiers in bioengineering and biotechnology (2021).
- The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI — Nature communications (2025)
Peer-reviewed article indexed in PubMed, published in Nature communications (2025).
- Targeting the FOXO4-p53 axis by retro-inverso peptide senolytic agents: a pharmacological strategy to mitigate brain aging and cognitive decline — Naunyn-Schmiedeberg's archives of pharmacology (2026)
Peer-reviewed article indexed in PubMed, published in Naunyn-Schmiedeberg's archives of pharmacology (2026).
- FOXO4-DRI regulates endothelial cell senescence via the P53 signaling pathway — Frontiers in bioengineering and biotechnology (2025)
Peer-reviewed article indexed in PubMed, published in Frontiers in bioengineering and biotechnology (2025).
- FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation — Communications biology (2025)
Peer-reviewed article indexed in PubMed, published in Communications biology (2025).
- FOXO4-DRI improves spermatogenesis in aged mice through reducing senescence-associated secretory phenotype secretion from Leydig cells — Experimental gerontology (2024)
Peer-reviewed article indexed in PubMed, published in Experimental gerontology (2024).
- FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice — Aging (2020)
Peer-reviewed article indexed in PubMed, published in Aging (2020).
PepIndex describes what literature exists. We do not interpret it, assess clinical significance, or publish quantities, protocols or instructions for use.
Vendor comparison
| Vendor | Score here | Price / mg | Certificates | Mean purity | Label deviation | Get it |
|---|---|---|---|---|---|---|
| PeptidePlugs | 89.790% | — | 1 | 99.1% | 13.3% | |
| Good Science Bio | 78.775% | $14.00 (68%) | 0 | — | — | |
| BioLongevity Labs | 65.774% | $27.50 (133%) | 0 | — | — |
Certificate records
| Vendor | Lot | Tested | Lab | Labeled | Assayed | Discrepancy | Purity | Source |
|---|---|---|---|---|---|---|---|---|
| PeptidePlugs | 103-08-ZB | Freedom Diagnostics Testing | 10 mg | 11.33 mg | 13.3% | 99.1% | Vendor-published |